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Abstract
Objective. SSc is a severe, heterogeneous multi-organ disease where population-based estimates on phenotypic
spectrum, overall disease burden and societal impact are largely missing. Here the objective was to provide the
first-ever complete national-level data on phenotype and major organ afflictions in SSc.
Methods. A stepwise strategy was applied to find and characterize every SSc patient resident in Norway from
2000 to 2012. First we identified every case in the country registered with an International Classification of
Diseases, Tenth Revision code for SSc (M34). Next we manually reviewed all cases coded as M34 to determine
whether they met the 1980 ACR and/or 2013 ACR/EULAR classification criteria for SSc and could be included
in the Norwegian SSc cohort (Nor-SSc). Finally, all disease features from SSc onset to study end were
reviewed.
Results. The Nor-SSc cohort included 815 SSc patients. The mean age at diagnosis was 53 years, with 84%
females and 77% limited cutaneous SSc. The estimated incidence increased from 4 per million in 2000 to 13 per
million in 2012. We identified high cumulative frequencies of internal organ involvement, coexistence of multiple
organ afflictions across disease subsets and autoantibody status and stable frequencies of pulmonary arterial
hypertension across haemodynamic definitions, but indications of referral-related differences in pulmonary hyperten-
sion detection rates across the study area.
Conclusion. This nationwide cohort study provides new, unbiased evidence for a high disease burden in SSc
patients of Caucasian descent and indicates the existence of hurdles preventing equality of assessment across the
SSc population.
Key words: systemic sclerosis, epidemiology, pulmonary hypertension, interstitial lung disease, gastrointes-
tinal involvement
Rheumatology key messages
. Incidence and prevalence rates of systemic sclerosis increased over the study period of 13 years.
. There was a high cumulative coexistence of multi-organ disease in SSc patients.
. The percentage of SSc patients referred to right heart catheterization varied across the study area.
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Introduction
SSc is a heterogeneous disease with large interindivid-
ual differences in skin involvement, internal organ afflic-
tions, disease progression and outcome [1–7]. An
increasing number of randomized clinical trials (RCTs) in
SSc has been conducted in recent years and despite
their limitations, they are the gold standard research
method for determining clinical management [8–12].
However, other approaches, including long-term follow-
up population-based studies, would be more suitable in
many SSc related research issues. Obvious examples
are critical outcome measures like mortality, target
organ damage, risk of cancer and cardiovascular dis-
ease, health-related quality of life and societal burden of
disease. The same holds true when studying the dis-
crepancy of conducted diagnostic testing and treatment
practices within a defined study area. Moreover, there
are still substantial knowledge gaps in SSc epidemiology
and how the spectrum of the disease is distributed in
unselected cohorts.
Inherent properties of the health care system makes
Norway one of the few countries worldwide were it is
possible to establish nationwide population based
cohorts [13, 14]. In Norway, there is universal public
health care and all patient contacts are registered in
electronic patient journal systems using the International
Classification of Diseases, Tenth Revision (ICD-10) cod-
ing system (the ICD system has been in use since
1999). Since every inhabitant in Norway has a unique
11-digit personal identification (ID) number, there is no
loss to follow-up during observation. Rheumatology
departments at public hospitals, of which there are 17,
including 4 at university hospitals, have the primary re-
sponsibility for SSc care in Norway, and our previous
work from the south-east Norway area showed that
every SSc patient in that area was followed at a depart-
ment of rheumatology [14]. Finally, Norway is a relatively
small country, which in January 2013 had 5.05 million
inhabitants (86% of Norwegian ethnicity, 6% Western
and 8% non-Western immigrants). These circumstances
make it fully feasible to identify every single diagnosed
patient resident in Norway within a defined time period.
In the present study, we aimed to include all SSc
patients in Norway in a prospective, nationwide
Norwegian SSc (Nor-SSc) cohort to provide national-
level unbiased epidemiologic data on SSc, estimate the
frequency of organ afflictions, with special emphasis on
pulmonary hypertension, and establish a platform for
understanding the overall impact of SSc on the society.
Methods
Stepwise case-finding strategy
The method was partly described previously [15]. In de-
tail, we captured all SSc patients resident in Norway be-
tween 2000 and 2012 and applied a stepwise strategy.
In 2013 we searched through the administrative data-
bases of all public hospitals in Norway and the
databases of the 12 private rheumatologists in the coun-
try to identify all patient contacts coded by ICD-10 as
M34.0, M34.1, M34.8 and M34.9 (SSc) at least once
during the study period. Next we used the 11-digit
Norwegian personal ID number system to control for du-
plicate registrations and patients with registrations at
more than one location. Additionally we identified cases
that were already included in the prospective Oslo
University Hospital SSc cohort and registered in the
Norwegian Systemic Connective Tissue Disease and
Vasculitis Registry (NOSVAR) registry.
In the second step, performed from 2013 to 2017, we
reviewed in detail the electronic patient journal of every
patient who was resident in Norway between 2000 and
2012 and registered at least once with an M34 code,
recording relevant disease parameters in a predefined
patient form. In patients who were already included in
the NOSVAR, we added registry data to the electronic
patient journal data and merged these in the patient
form. The major purposes of this detailed review were to
determine whether the patient met the study cohort in-
clusion criteria (see below) and to retrieve and systemat-
ically record longitudinal data on disease features from
the time of diagnosis to the end of the inclusion period
on 1 January 2013, or death.
Inclusion and exclusion criteria for the Nor-SSc
cohort
Patients identified by the stepwise case-finding strategy
were included in the Nor-SSc cohort if they met the fol-
lowing criteria: age >18 years, clinical SSc diagnosis,
fulfilment of the 1980 ACR and/or 2013 ACR/EULAR
SSc classification criteria and findings not better
explained by another disease. We included patients with
overlap diseases if they met these criteria, but excluded
all M34-coded patients who had connective tissue dis-
eases other than SSc, localized scleroderma or
morphea.
This study complied with the Declaration of Helsinki.
The Regional Committee of Health and Medical
Research Ethics in south-east Norway approved the
study and received exemption of informed consent for
identification of the patients and chart review (2009/
1035).
Recording of demographic data and disease
features ever present
For each patient, we recorded available data on the
time of onset of RP and the first non-RP symptom, time
of clinical SSc diagnosis, SSc subset defined as sine
scleroderma SSc, lcSSc and dcSSc [16]. Data on modi-
fied Rodnan skin score and nailfold capillaroscopy were
registered [17–19]. Digital ulcers, calcinosis, telangiecta-
sia, scleroderma renal crisis (SRC), tendon friction rub,
dysphagia, diarrhoea, obstipation and faecal incontin-
ence were recorded in the patient chart if ever present.
Myositis was evaluated by clinical diagnosis and/or
positive biopsy; gastroesophageal reflux disease was
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evaluated by upper endoscopy and/or pH measurement
and/or patient-reported symptoms of gastroesophageal
reflux disease. Oesophagus dysmotility was defined by
dynamic X-ray and gastric antral vascular ectasia
(GAVE) by upper endoscopy [9, 20, 21].
Data from serum autoantibody tests were obtained by
a review of each patient’s laboratory results. Methods for
the detection of ANA were IIF or ELISA. ACA and anti-
topoisomerase antibodies (ATAs) were always detected
by ELISA. Anti-RNA polymerase III, anti-fibrillarin, anti-Th/
To, NOR90, U1-RNP, kU and PmScl75/100 were
detected by immune blot (SSc blot, Euroimmun,
Luebeck, Germany) and scored according to the manu-
facturer’s protocol.
Assessment of cardiopulmonary involvement,
including pulmonary hypertension
Echocardiography parameters, 6 min walking distance
test (6MWD), N-terminal pro-brain natriuretic peptide
(NT-proBNP), pulmonary function tests and high-reso-
lution CT (HRCT) lung images from baseline and the last
available follow-up visit were noted [14, 22]. All HRCTs
were reviewed manually as described [22]. Reticular pat-
tern abnormalities and superimposed ground-glass
opacities were defined as equivalent to fibrosis and the
extent of pulmonary fibrosis was expressed as a per-
centage of total lung volume [23]. Pulmonary function
tests with diffusing lung capacity for carbon monoxide
(DLCO), forced vital capacity (FVC) and forced expira-
tory volume during the first second (FEV1) were carried
out according to American Thoracic Society/European
Respiratory Society (ERS) guidelines as described [22].
Right heart catheterization (RHC) was registered if con-
ducted and pulmonary hypertension (PH) was diagnosed
according to the 2015 European Society of Cardiology/
ERS guidelines as mean pulmonary arterial pressure
(mPAP) 25 mmHg and borderline PH as mPAP 20–
24 mmHg [24, 25]. Patients were further classified as
pre- and post-capillary PH, based on a threshold pul-
monary capillary wedge pressure (PCWP) of 15 mmHg
[24, 26]. Additionally we applied the new haemodynamic
definitions for PH proposed by the 6th World
Symposium on Pulmonary Hypertension (WSPH) with
pre-capillary PH defined by mPAP >20 mmHg, PCWP
15 mmHg and pulmonary vascular resistance (PVR)
3.0 Wood units (WU) [27]. We also included analyses
of lower PVR threshold values (PVR 2.5 and 2.0 WU).
PAH [World Health Organization (WHO) group 1] was
diagnosed as described [22, 28] by the presence of pre-
capillary PH; the absence of significant interstitial lung
disease (ILD), defined as <10% lung fibrosis by HRCT
at baseline and follow-up investigations and/or by a pre-
dicted FVC >70% at baseline and follow-up; or exclu-
sion of other pre-capillary PH causes. The PH-ILD (WHO
group 3) diagnosis was defined as pre-capillary PH
combined with lung fibrosis >10% on HRCT and/or FVC
<70%. In the absence of RHC, possible PH was noted
and defined as systolic pulmonary arterial pressure
(sPAP) >40 mmHg on the echocardiography, annual
decline in the DLCO >10% and/or unexplained function-
al class 4. Findings consistent with cardiovascular dis-
ease (angina pectoris and myocardial infarction) were
recorded if ever present.
Prevalence and incidence
Incident SSc cases were diagnosed from 2000 to 2012
while prevalent cases included patients diagnosed be-
fore 2000. The point prevalence of SSc was calculated
from all incident and prevalent cases alive on 1 January
2013. We calculated the frequency of incident SSc
patients year by year from 2000 to 2012. Incidence rates
were expressed as the number of cases per million
inhabitants >18 years of age per calendar year and pre-
sented with 95% CIs.
Statistics
Registration forms were scanned (Cardiff TeleForm ver-
sion 9) and manually checked and imported to an
Access 2016 database (Microsoft, Redmond, WA, USA).
Analyses were performed with SPSS version 25 (IBM,
Armonk, NY, USA) and STATA version 15 (StataCorp,
College Station, TX, USA). Descriptive data are pre-
sented as numbers and percentages, mean with S.D. or
median with range. Comparisons between groups were
evaluated with independent sample t test and Mann–
Whitney U test, as appropriate. For analysing correla-
tions, Pearson or Kendall’s sb coefficients were applied.
Results
Case-finding strategy, patient demographics and
population prevalence of SSc
In the initial case-finding step, we searched across all
patient administrative databases in the country and
identified 2468 patient contacts registered at least once
with an M34 code (M34.0, M34.1, M34.8 or M34.) in at
least one database during the time period from January
2000 to December 2012. By merging all these M34-
coded patient contacts against national ID numbers, we
found that 1205 of the 2468 cases identified were regis-
tered in more than one database (i.e. at more than one
location). Removal of these duplicate registrations left us
with 1263 unique patients (Fig. 1).
In the second step, we performed a detailed electron-
ic patient journal review on the 1263 unique patients
who had been registered at least once with an M34
code between 2000 and 2012. A total of 367 of the
1263 patients had to be excluded because their clinical
features were not compatible with SSc. Most of the
excluded cases had an incident chronic rheumatic dis-
ease other than SSc and had been registered as M34
on a single occasion, typically early in their disease
course. Additionally, we excluded 81 patients who had
one or more SSc-associated disease feature but failed
to meet the SSc classification criteria (demographics
in online Supplementary Table S1, available at
Rheumatology online). After having excluded these 448
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(367þ 81) patients, we were left with a cohort of 815
cases who had clinical SSc by chart review and met all
the Nor-SSc cohort inclusion criteria.
Of the 815 patients in the final Nor-SSc cohort, 630
(77%) were defined as incident cases (i.e. diagnosed
from 2000 onwards) while 185 (23%) were prevalent
cases (i.e. diagnosed before 2000). As expected from
the structure of the Norwegian health care system,
we found that the 815 patients in the cohort were pri-
marily referred to a rheumatologist for diagnostic proce-
dures and follow-up. It appeared that 404 of the 815
Nor-SSc patients (49.6%) were already included in
the prospective SSc cohort at Oslo University Hospital
[14].
Patient demographics are shown in Table 1. By 1
January 2013 a total of 161 patients (19.9%) were
deceased (Table 1). The estimated point prevalence
of SSc in Norway on 1 January 2013 was 13/100 000
(95% CI 12.0, 13.9), with 5/100 000 (95% CI 4.1, 5.9)
in males and 22/100 000 (95% CI 20.2, 23.9) in
females. The number of newly diagnosed SSc
patients per year increased from 20–42 cases each
year in the time period 2000–2004 to 50–64 cases in
2005–2012 (Fig. 2A), corresponding to an estimated
mean annual SSc incidence of 4–6 per million in the
time period 2000–2004 and 10–13 per million in
2005–12.
Overview of autoantibodies and cumulative
incidence of disease features
Test results for ANAs were available in 99.6% of the co-
hort patients and were positive in 93%. The frequency
of specific autoantibodies and cumulative incidences of
specific organ manifestations are shown in Table 2 and
Fig. 2D.
Baseline lung CT data were available in 650 patients
and lung fibrosis, of varying degree, was identified in
324 of 650 patients (50%). The mean baseline FVC was
94% (S.D. 20.9) and the mean baseline DLCO was 69%
(S.D. 20.2), as previously published [15].
Multi-organ disease was highly common, with more
than two of six features being major disease features
[gastrointestinal (GI) involvement, skin affection, lung fi-
brosis, digital ulcers, PH and SRC] ever present in the
vast majority of the cohort patients, also when stratified
by antibody status or disease subtype (Fig. 3).
Development of PH during the observation period
As the chart review process indicated differences in
RHC referral practices by time and location (see below),
we reasoned that it would be most appropriate to esti-
mate accumulated PH frequencies at two levels: as def-
inite PH verified by RHC and as possible PH indicated
by sPAP >40 mmHg by echocardiography at baseline
and/or follow-up and additional annual decline in DLCO
>10% and/or unexplained functional class 4.
PH assessment by RHC was conducted in 190
patients (23%) (Fig. 4), with 160 (84%) having the RHC
procedure done at Oslo University Hospital. Thus the
proportion of patients examined by RHC was higher in
the Nor-SSc cohort subset ever examined at Oslo
University Hospital [160/404 (40%)] than among the sub-
set followed at any of the other hospitals [30/413 (7%);
P<0.001]. Additionally, it appeared that the annual
number of RHC examinations increased through the ob-
servation period, from 1–10 RHCs per year in 2000–
2008 to 10–15 per year in 2009–2012 and 15–22 in
2013–2016.
Pre-capillary PH by the 2015 guidelines was diag-
nosed in 91 of 190 patients subjected to RHC, with PAH
in 57 (7%) and PH-ILD in 34 (4%). The mean time from
disease onset to PAH diagnosis was 8.3 years (S.D. 8.4).
A total of 155 patients had complete hemodynamic val-
ues (including PVR) available, allowing for pre-capillary
PH evaluation by the new WSPH criteria (Fig. 4B). We
found that the prevalence of PAH defined by mPAP
>20 mmHg and PVR 3.0 WU was 5%. When lowering
the PVR limit to 2.5 and 2.0 WU the prevalence
increased to 6% and 7%, respectively. With PVR
3.0 WU as the cut-off, the frequency of PH-ILD cases
was 3%, increasing to 4% when lowering the PVR value
to 2.0 WU (Fig. 4B).
Baseline echocardiography was conducted in 728
patients (89%), with 103 (14%) having an estimated
sPAP >40 mmHg. Analyses of available follow-up echo-
cardiography in 398 patients (48%) showed that 61
FIG. 1 Case-finding strategy and patient inclusion in the
Nor-SSc cohort
Stepwise case-finding strategy (yellow boxes) and num-
ber of excluded patients (red boxes) and the number of
identified SSc patients in the Nor-SSc cohort segre-
gated by prevalent and incident cases (green boxes).
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FIG. 2 Prevalence and incidence in the Nor-SSc cohort
(A) The number of newly diagnosed SSc patients per year from 2000 to 2012. (B) Point prevalence of SSc in Norway
each year from 2000 to 2012. (C) Mean time (in months) from RP to first non-RP symptom (green) and time from first
non-RP symptom to diagnosis (red). (D) Distribution of SSc-related serum antibodies in the cohort. (E) Distribution of
SSc according to skin involvement. (F) Frequencies of skin and renal involvement and other organ manifestations. (G)
Frequencies of GI involvement. (H) Assessment of pre-capillary PH, with estimates for definite PH diagnosed by RHC
and possible PH by echocardiography and clinical parameters.
TABLE 1 Demographics, key SSc features and physical function in the total Nor-SSc cohort segregated by SSc subtype
Characteristics Total (N 5 815) dcSSc (n 5 141) lcSSc (n 5 629)
Demographics
Age at diagnosis, years, mean (S.D.) 53 (14.7) 49 (16.4) 54 (14.2)
Time from RP to non-RP, years, mean (S.D.)a 6.4 (10.3) 3.2 (9.0) 7.1 (3.4)
Time from non-RP to diagnosis, years, mean(S.D.)b 3.1 (5.1) 1.4 (3.0) 3.5 (5.5)
Female, n (%) 682 (83.7) 95 (67.4) 547 (87)
Observation period, years, mean (S.D.) 11.1 (7.7) 10.9 (9.2) 11.9 (7.4)
Deceased by 17 April 2017, n (%) 234 (28.7) 62 (44.0) 168 (26.7)
Key SSc features
Modified Rodnan skin score, median (range)c 5.0 (0-49) 18.0 (1-49) 4 (0-18)
Abnormal nailfold capillaroscopy, n (%)d 498 (94.4) 81 (95.3) 399 (95)
Physical function
Functional class 1 or 2, n (%)e 486 (59.6) 53 (28.5) 433 (68.8)
Functional class 3 or 4, n (%)e 112 (13.7) 23 (12.4) 89 (14.1)
6MWD, m, mean (S.D.)f 457 (149.6) 438 (161.4) 482 (145.9)
Analyses of pulmonary function tests
FVC, % predicted, mean (S.D.)g 94 (20.9) 83 (22.6) 97 (19.7)
DLCO, % predicted, mean (S.D.)g 69 (20.2) 63 (20.1) 71 (19.8)
Data were complete except for the following: aavailable in 573 patients, bavailable in 731 patients, cevaluated in 513
patients, devaluated in 525 patients, eevaluated in 598 patients, fevaluated in 379 patients and gavailable in 703 patients.
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patients (16%) with normal sPAP at baseline had devel-
oped new-onset sPAP >40 mmHg. Among the patients
having an estimated sPAP >40 mmHg by echocardiog-
raphy at baseline and/or follow-up, we identified 74
patients who had never been referred to RHC but had
an annual decline in DLCO >10% and/or unexplained
functional class 4 considered as compatible with PH.
These 74 patients were defined as possible PH cases,
with 44 classified as possible PAH and 30 as possible
PH-ILD. By adding together the cases with definite pre-
capillary PH by RHC (>25 mmHg) and possible PH, we
found an estimated cumulative PH incidence in the Nor-
SSc cohort of 19% (165/815), with 11% being PAH and
8% PH-ILD cases. This total estimate was identical to
the pre-capillary PH frequency observed in the patient
subsets with RHC from Oslo University Hospital
(n¼160), but the relative frequency of PAH and PH-ILD
in this subset was slightly different, with 12% having
PAH and 7% PH-ILD.
Plasma NT-proBNP at baseline was available for 460
patients (56%) with a mean value of 86.2 pmol/l (S.D.
312.8). Follow up NT-proBNP was available for 367
patients (45%), with a mean value of 195.1 pmol/l (S.D.
684.2).
Discussion
Studies of population-based patient cohorts derived
from well-defined areas are needed to fully appreciate
the overall impact of a disease. Here we present data
from the first complete nationwide cohort study on SSc.
Major findings were increasing incidence and prevalence
rates of SSc throughout the study period, high cumula-
tive coexistence of multi-organ disease and indications
of referral-related differences in PH detection across the
study area. Overall, we believe that the results provide
unbiased evidence for a very high disease burden in
SSc patients of Caucasian descent and indicate unmet
needs for equality of assessment.
With entries for >16 000 SSc patients from >150
countries, the EULAR Scleroderma Trials and Research
group (EUSTAR) database is definitely an immense
source of knowledge and a unique platform for SSc re-
search [7, 29–31]. Recruitment policies are heteroge-
neous across EUSTAR centres and there are no
requirements to register all patients. A large proportion
of centres, particularly the large centres, recruit all of
their patients into the database, but it is not required. It
is therefore unknown whether the spectre of disease
seen in the EUSTAR patient population mirrors that of
an unselected population-based SSc cohort [4, 32].
Although the estimated point prevalence of SSc at the
study end was still within the range reported from re-
gional studies performed in other northern European
countries, we observed a steady increase in point
prevalence of SSc throughout the 13 year study period
[33]. We cannot exclude the possibility of a true increase
in the incidence of SSc, but favour the explanation that
it is due to increased SSc awareness throughout Europe
in recent years. Thus it is noteworthy that the diagnostic
delay (i.e. the time from the first SSc symptom to
TABLE 2 Autoantibody profile and organ involvement in the total Nor-SSc cohort and segregated by SSc subtype
Characteristics Available, N (%) Total, N (%) dcSSc (n 5 141) lcSSc (n 5 627)
Antibodies 806 (98.9)
ACA, n (%) 497 (61.7) 11 (7.8) 451 (72.9)
ATA, n (%) 91 (11.3) 47 (33.3) 45 (7.3)
Anti-RNAP3, n (%) 46 (5.7) 38 (27.1) 8 (1.3)
Organ involvement
Lung fibrosis, n (%) 650 (79.8) 324(49.9) 94 (75.4) 217 (44.4)
Digital ulcers, n (%) 793 (97.3) 301 (38.0) 62 (44.6) 234 (38.4)
Calcinosis, n (%) 704 (86.4) 260 (36.9) 30 (24.4) 218 (40.7)
Telangiectasia, n (%) 739 (90.7) 556 (75.2) 79 (60.8) 449 (79.8)
SRC, n (%) 782 (96.0) 26 (3.3) 20 (14.5) 6 (1.0)
Tendon friction rub, n (%) 594 (72.9) 18 (3.0) 18 (18.2) 1 (0.2)
Myositis, n (%)a 753 (92.4) 18 (2.4) 8 (5.9) 9 (1.6)
Oesophagus dysmotility, n (%)b 664 (81.5) 531 (80.0) 109 (87.2) 404 (79.4)
GERD, n (%)c 683 (83.8) 430 (63.0) 80 (64.0) 335 (63.4)
Dysphagia, n (%) 732 (89.8) 429 (58.6) 78 (60.9) 328 (58.4)
Constipation, n (%) 608 (74.6) 131 (21.5) 32 (26.7) 95 (20.5)
Diarrhoea, n (%) 627 (76.9) 187 (29.8) 41 (34.2) 144 (29.8)
Faecal incontinence, n (%) 564 (69.2) 93 (16.5) 25 (22.9) 67 (15.4)
GAVE, n (%)d 456 (56.0) 37 (8.1) 13 (16.5) 24 (6.6)
aEvaluated by barium esophagram. bEvaluated by clinical diagnosis and/or biopsy. cEvaluated by finding on upper endos-
copy and/or pH measurement and/or patient-reported symptoms of GERD. dDiagnosed by upper endoscopy. RNAP3: RNA
polymerase III; GERD: gastroesophageal reflux disease, defined by patient-reported symptoms and/or findings on gastros-
copy/pH measurement. % is calculated using number of patients with available data as the denominator.
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diagnosis) remained the same across the study period.
This observation probably mirrors the referral delay re-
cently shown by Distler et al. [34] and emphasizes the
persisting educational needs of referring physicians and
patients.
There is an ongoing discussion concerning the hemo-
dynamic definitions for PH diagnosis, with recently pro-
posed new definitions lowering the mPAP value to
>20 mmHg and including a conservative PVR cut-off
value 3.0 WU to capture all patients with manifest pre-
capillary PH [27]. However, this threshold is arbitrary
and it has been suggested that a PVR >2.0 WU should
be regarded as abnormal [26]. Applying the proposed
definitions with a PVR cut-off value of 3.0 WU did not
have a major impact on the number of patients diag-
nosed with pre-capillary PH. Further studies are needed
to explore whether a cut-off value of PVR 3.0 WU is
appropriate in SSc patients.
Although the overall estimates of organ afflictions in
Nor-SSc indicated that GI and cardiopulmonary involve-
ment were highly common, we observed differences in
certain afflictions, particularly PH, across the study area.
More detailed analyses indicated that the cumulative in-
cidence of PH varied between local and academic
centres and was dependent on the number of RHCs
conducted at the different centres. Screening recom-
mendations for PH include annual echocardiography
assessments, and RHC referral is indicated if there are
abnormal echocardiography findings in the context of
clinical PH suspicion [24, 26]. However, annual echocar-
diography and RHC is not easily available in all centres
following SSc patients, and there are no existing data
on how often echocardiography and RHC are conducted
in academic compared with non-academic centres.
These circumstances might have had implications for
previously reported data regarding PH and indicate that
FIG. 3 Cumulative coexistence of six major disease features
Cumulative coexistence of six major disease features including GI involvement, skin affection, lung fibrosis, digital
ulcers, PH and SRC stratified by antibody status or disease subtype with (A) all patients, (B) patients positive for anti-
topoisomerase I antibody, (C) patients positive for ACAs, (D) patients positive for anti-RNA polymerase III antibody,
(E) lcSSc patients and (F) dcSSc patients.
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we are still in need of increased PH awareness, better
and standardized PH screening methods and guidelines
on referral to expert centres for RHC independent of
haemodynamic definitions of PH. The same argument is
most likely valid for GI involvement, for which no gener-
alized screening recommendations exist. This results in
differences between centres, such as the varying fre-
quency of GAVE screening by upper endoscopy noted
across the Nor-SSc cohort. With the aim of standardiz-
ing the follow-up of patients with SSc, a Delphi-based
expert consensus was recently published that will hope-
fully lead to an adequate standard of care for all patients
with SSc and enhance the standardization and hom-
ogenization of the practices worldwide [35].
The main strengths of our study were the comprehen-
sive inclusion and identification strategies. All diagnosed
SSc patients in Norway were included in the Nor-SSc
cohort and all diagnoses of every patient were con-
firmed by chart review. Due to the health system in
Norway, we did not have any loss to follow-up and vital
status was available for all patients. Additionally, a high
percentage of patients had follow-up data available to
estimate the longitudinal development of certain organ
involvements. Despite the comprehensive and complex
strategies applied to include all patients in the country,
we still might have missed some patients with SSc due
to miscoding. However, the fact that colleagues at Oslo
University Hospital who applied similar ICD-10-based
case-finding strategies for other connective tissues dis-
eases (inflammatory myopathies, SLE and MCTD) did
not find any SSc patients who were not already regis-
tered in the Nor-SSc cohort underscores the complete-
ness of our cohort [36–38].
The main limitations were a study design that could
only estimate the frequency of new SSc diagnoses per
year, but not the true incidence. Additionally, we did not
have complete coverage of longitudinal clinical data in
all the patients, possibly influencing the prevalence of
certain organ manifestations. Chart review was per-
formed by a rheumatologist experienced with SSc, but
clinical assessment in the different centres could have
been performed by a rheumatologist with less experi-
ence. Finally, we might have missed patients with very
mild forms of the disease, who do not necessarily seek
health care but still could fulfil the 2013 classification
criteria.
In conclusion, we provide the first real-life data on
prevalence and incidence, organ involvement and the
impact of SSc on a nationwide level. The results strong-
ly support the notion that SSc is a rare, heterogeneous
disease with a high disease burden. They also indicate
that Norway, probably like most other countries, has not
yet reached the aim of achieving equality of assessment
and care throughout the nation.
FIG. 4 Frequency of PH assessed by RHC
(A) Cumulative incidence of PH subsets during the study period according to the current PH definition. (B)
Cumulative incidence of PAH, PH-ILD and borderline PH in patients with available PVR values (n¼155) and the num-
ber of patients fulfilling the newly proposed pre-capillary PH definition and PVR >2.5 WU and >2.0 WU.
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